Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Sponsor content
359 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENFLONSIA clesrovimab 105 mg in 0.7 mL solution for injection prefilled syringe.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: belzutifan.
-
Prescription medicine decision summaryEnflonsia has been approved to help prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Prescription medicine registrationActive ingredients: sotatercept.
-
Prescription medicine registrationActive ingredients: clesrovimab.
-
Prescription medicine registrationActive ingredients: pembrolizumab.